Company Description
Medikra is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical-grade botanical therapeutics.
Through its wholly owned Malaysian subsidiary, Medika Natura Sdn. Bhd., the Company has established an integrated discovery and development platform that combines proprietary botanical extraction, preclinical and clinical trials, and multi-omics research.
This platform aims to transform traditional medicinal plants into scientifically tested therapies aligned with international regulatory standards.
The Company aims to address unmet medical needs in metabolic diseases, women’s health, chronic inflammation, and oncology.
Medikra seeks to advance its development programs through both pharmaceutical and nutraceutical pathways in alignment with globally recognized regulatory frameworks.
| Country | Malaysia |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Abdul Razak bin Mohd Isa |
Contact Details
Address: Unit 1.02, The Bousteador 10, Jalan PJU 7/6, Mutiara Damansara Petaling Jaya, Selangor 47800 Malaysia | |
| Phone | +603 2380 0319 |
Stock Details
| Ticker Symbol | MDKR |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002078035 |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Abdul Razak bin Mohd Isa | Chief Executive Officer and Executive Director |
| Mustadza bin Muhamad | Chief Operating Officer and Executive Director |
| Goh Sai Keong | Chief Financial Officer |
| Datuk Ali Abdul Kadir | Chairman of the Board of Directors |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 13, 2026 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Jan 20, 2026 | F-1 | Registration statement for certain foreign private issuers |
| Nov 20, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Aug 22, 2025 | DRS | [Cover] Draft Registration Statement |